NCT07523880 Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD
| NCT ID | NCT07523880 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xueyan Zhao |
| Condition | Thrombosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 12,154 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2029-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 12,154 participants in total. It began in 2025-08-01 with a primary completion date of 2029-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with coronary heart disease who take dual antiplatelet therapy face two serious risks: thrombosis and major bleeding. This study aims to develop better ways to predict these risks and guide personalized treatment. The investigators will use a large, long-term follow-up study of Chinese patients with coronary heart disease. This research plans to discover new biomarkers related to clot and bleeding risk. The study will combine information from proteins, metabolites, sugars attached to proteins, genes, and medical images. Using machine learning methods, the investigators will identify the most important markers and test them in the patient group of this study. The investigators will then build new risk prediction models that include these new markers together with traditional risk scores (such as GRACE, PARIS, and Precise-DAPT). This study will check whether these new models are better than existing ones at predicting who will develop clots or bleeding and at helping doctors decide on the best treatment for each patient. The new aspects of this research are: (1) using advanced multi-omics technology to find novel markers specifically for Chinese patients; (2) combining clinical, biological, and imaging data to improve prediction accuracy; and (3) using machine learning to create more precise risk models. The goal is to provide doctors with a more accurate tool to assess each patient's risk of clots and bleeding. This will help them choose the safest and most effective antiplatelet treatment, reduce serious complications, and improve patient care.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years. 2. Hospitalized due to symptoms or objective evidence of coronary heart disease and planned for long-term antithrombotic therapy. 3. Diagnosis of acute coronary syndrome or stable coronary heart disease undergoing percutaneous coronary intervention (PCI), with clinical stability meeting discharge criteria after treatment. 4. For patients from the existing cohort: minimum 2 years of follow-up with complete clinical data and blood specimens available; approval for use of these data and specimens has been obtained, with a waiver of re-consent. For newly enrolled patients: voluntary written informed consent provided by the patient or legal representative, agreement to provide blood samples, and acceptance of follow-up procedures. Exclusion Criteria: For patients from the existing cohort: 1. Severe missing or erroneous baseline or clinical data that cannot be corrected by source verification. 2. No available blood specimen, or specimen that does not me
Frequently Asked Questions
Who can join the NCT07523880 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Thrombosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07523880 currently recruiting?
Yes, NCT07523880 is actively recruiting participants. Visit ClinicalTrials.gov or contact Xueyan Zhao to inquire about joining.
Where is the NCT07523880 trial being conducted?
This trial is being conducted at Zhengzhou, China, Shenyang, China, Beijing, China.
Who is sponsoring the NCT07523880 clinical trial?
NCT07523880 is sponsored by Xueyan Zhao. The trial plans to enroll 12,154 participants.